MTOR and hepatocellular carcinoma: In addition to studies on the combination of mTOR inhibitors with conventional chemotherapeutic agents, two phase I/II clinical studies are currently recruiting patients with advanced HCC to determine the safety/toxicity profile of temsirolimus in combination with sorafenib (Table 1).